donanemab
Selected indexed studies
- Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. (JAMA, 2023) [PMID:37459141]
- Donanemab in Early Alzheimer's Disease. (N Engl J Med, 2021) [PMID:33720637]
- Donanemab: Appropriate use recommendations. (J Prev Alzheimers Dis, 2025) [PMID:40155270]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis. (2024) pubmed
- Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. (2023) pubmed
- Donanemab in Early Alzheimer's Disease. (2021) pubmed
- Donanemab: Appropriate use recommendations. (2025) pubmed
- Donanemab: First Approval. (2024) pubmed
- Donanemab. (2012) pubmed
- Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit. (2024) pubmed
- Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension. (2026) pubmed
- Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials. (2025) pubmed
- Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease. (2023) pubmed